Compare DexCom, Inc. (DXCM) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs H2O America — how do they compare? DexCom, Inc. trades at $76.86 (market cap $28.06B), while H2O America trades at $64.47 (market cap $2.62B). The key difference: DexCom, Inc. is far larger — about 10.7× H2O America's market cap, and H2O America pays a 2.81% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | HTO | |
|---|---|---|
Market Cap | $28.06B | $2.62B |
Sector | Health | Technology |
52-Week High | $89.53 | $62.94 |
52-Week Low | $54.84 | $44.44 |
Enterprise Value | $27.03B | $4.34B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
HTO trades at $63.94, up 1.59% with strong technical momentum as moving averages signal bullish sentiment. The stock shows solid fundamentals with 12.87% net income margin and consistent earnings beats in three of the last four quarters. Recent corporate actions include a $0.44 dividend payment scheduled for June 2026, while analyst consensus remains strongly positive with 80% buy ratings.
The outlook remains favorable given HTO's stable utility business model and projected EPS growth. Key risks include high capital expenditure requirements and sensitivity to regulatory rate changes. With the current price near analyst targets, further upside may depend on Q2 2026 earnings exceeding expectations when reported on July 27, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
